Collaborations with research and commercial teams to identify and collect data needed to increase market share and expand claims.

Responsible for all Clinical Affairs activities including clinical strategy for all business units, coordination of Clinical Affairs and Compliance activities; integration of Clinical Affairs with Medical Affairs projects (clinical and otherwise), maintenance of critical Clinical Affairs procedures and policies and Clinical Affairs personnel and team management.Player/coach with continued responsibilities as the principal liaison between Medical Affairs and Medline business units as outlined below.

Principal liaison between the wound healing, skin care and infection control business units and the medical affairs organization.Guide the development of clinical needs assessments to link business goals to clinical initiatives.Oversee clinical trial initiatives including design, development and execution of all wound healing studies. Represent Medline and its programs to external audiences, including medical and regulatory communities, as well as industry collaborators and partners. Establish, in partnership with Commercial Operations, the medical education materials and programs that will drive adoption of products into Standard of Care.Develop new and nurture existing relationships with key opinion leaders, clinical investigators, physicians, pharmaceutical companies, laboratories, and payers regarding advances, collaborative studies, and product related issues to foster acceptance of the Company’s products.Leadership and direction of the company’s pipeline of clinical development programs.Member of the management team determining focus and activities for research and development and helping set the overall strategic direction of the wound healing business.Assist facilities with all clinical implementation of our products; including protocols, in-service training and other capabilities to strengthen introduction of our product into facilities.

Supported the Precision development teams on design of research studies (protocols, analyses, data sources) intended to address health economic, outcomes research and health policy questions using a range of potential technical approachesSynthesized, interpreted and communicated the results of these studies to Precision stakeholders and the research clients and I advise on written technical reports, peer-reviewed manuscripts, and presentations of the research.

Executive leader with responsibility for the Americas Scientific Affairs and business development activities to expand the existing customer base and develop new markets for The Binding Site. I championed and led the development of an HEOR (Health Economics Outcomes Research) model to demonstrate the clinical and economic value of the early diagnosis of multiple myeloma. Conservative calculations showed that an up-front investment in guideline-recommended testing could significantly the reduce time to diagnosis, lessen the frequency of complications (anemia, renal, bone, infections and neurological) and could provide a 10-fold return on investment.I was the executive representative for Quality for the US subsidiary of The Binding Site and guided the development of a new Quality Management System for the subsidiary.

Scientific Affairs are field-based, customer-facing scientists who serve as clinical, technical and scientific liaisons between the company and it's physician, scientist and healthcare customersI led a team of five Ph.D.s and Med Techs responsible for the North America Scientific Affairs activities across several product lines (cardiac, blood gas and electrolytes, and infectious diseases) and two sales organizations (hospital and physician office). These activities included technical, clinical, scientific, regulatory and implementation consulting, training and medical education. Publications:Led the creation and execution of a 6-site, 13-assay, 191-sample troponin assay correlation study (JALM (2017) vol 1, pp. 544-561).Devised the diagnostic testing for a study of point-of-care troponin testing in ambulances (The PROACT study: Can J Card (2014) vol 30, pp 1208-1215 and J. Am. Heart Assoc (2015) vol 4, e002859)Industry representative on the CAP Point of Care Committee (Feb 2012 to present).

An individual contributor in Scientific Affairs. Developed and maintained relationships with key opinion leaders (cardiologists and laboratory personnel) and sponsored post-market clinical studies to build product awareness and advocacyCreated educational programs (symposia) to promote brand awarenessFrequent invited speaker at laboratory society meetingsContributing author on the CLSI Guidance document: POCT09: Selection Criteria for Point-of-Care Testing Devices and Co-author of a Point of Care Testing chapter of The Immunoassay Handbook.

My team and I were the scientific face for the company. We served as clinical, technical and scientific liaison between Abbott Diagnostics and it's customers. We were responsible for the higher level training of the same for the sales reps.In this short time, I grew the department from a single individual contributor to a team of four Scientific Affairs Managers.

Prior to Scientific Affairs I led many projects and project teams at Abbott. Teams under my supervision developed and launched an automated immunoassay for cyclosporine. I then led the teams that manufactured and provided technical support for that assay and it's sister products. I returned to R&D where I led teams doing assay design, Quality Systems overhaul and OEM product development projects. These early years at Abbott gave me experience in product development, commercialization, manufacture and on-market technical support.